News Sentiment

BIAF sentiment intelligence

bioAffinity Technologies, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 35 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 0.70 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-8.2% over one week, -15.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Transcript : BioAffinity Technologies, Inc. - Special Call

Market Reaction

Price moving ahead of tone

70/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction -8.2% Price reacting lower
Trend fit Trend inactive -15.9% over four weeks
Fair value -97.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 15
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
TradingView 4
Market source 3
Investing.com 2
Moomoo 2
PR Newswire 2
marketscreener.com 1
www.marketscreener.com 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 4
Deals and strategy 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 35
www.marketscreener.com Direct company coverage

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a lock-up agreement that concludes on July 19, 2026. This agreement restricts officers and directors from selling or otherwise disposing of their common stock for 31 days, from June 18, 2026, to July 19, 2026,

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 03:41
Source
www.marketscreener.com
Medical Product Outsourcing Direct company coverage

bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech

bioAffinity Technologies is launching a pilot study with Brooke Army Medical Center to develop diagnostic tests for asthma and COPD. This research aims to identify inflammatory biomarkers using their proprietary flow cytometry+AI technology to personalize treatment approaches. Th

Tone
Positive 71/100
Event
Market update
Published
15 Jul 2026 14:12
Source
Medical Product Outsourcing
TradingView Direct company coverage

bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings

This page provides access to SEC filings and other financial documents for bioAffinity Technologies, Inc. (BIAFW). It lists various reports including 10-K, 10-Q, and 8-K filings from 2022 to the projected Q1 FY2026, detailing earnings releases, corporate events, and operational u

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 13:09
Source
TradingView
Market source Direct company coverage

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?

Shares of bioAffinity Technologies, Inc. (BIAF) have plummeted 77% in the past three months, significantly underperforming its industry and market benchmarks despite strong year-over-year growth in commercial sales for its CyPath Lung product and promising preclinical findings. T

Tone
Negative 37/100
Event
Market update
Published
09 Jul 2026 17:44
Source
Market source
Business Wire Direct company coverage

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

bioAffinity Technologies announced a significant increase in commercial sales for its CyPath® Lung diagnostic test, with sales for Q2 2026 doubling year-over-year and growing over 30% from the previous quarter. This growth is attributed to increased utilization by existing client

Tone
Positive 82/100
Event
Earnings
Published
08 Jul 2026 00:11
Source
Business Wire
TradingView Direct company coverage

bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year

bioAffinity Technologies reported a significant increase in CyPath® Lung commercial sales, more than doubling year-over-year in Q2 2026 and growing over 30% sequentially. This surge was driven by higher utilization among existing clients and a 155% rise in ordering physician offi

Tone
Positive 82/100
Event
Market update
Published
07 Jul 2026 13:11
Source
TradingView
Investing.com Direct company coverage

bioAffinity reports 200% jump in lung test sales year-over-year

bioAffinity Technologies (NASDAQ:BIAF) announced a significant increase in sales volume for its CyPath Lung diagnostic test, reporting a 200% year-over-year jump in Q2 2026 and 30% growth quarter-over-quarter. Despite a 91% stock price drop over the past year, InvestingPro analys

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 13:11
Source
Investing.com
TradingView Direct company coverage

bioAffinity Technologies reports accelerated CyPath Lung sales, Philips partnership to boost veteran screening

bioAffinity Technologies announced a significant increase in CyPath Lung unit sales, with April sales up nearly 300% year-over-year. The company also reported a 69% rise in ordering physician offices and clinics. Furthermore, bioAffinity is partnering with Philips and 4DMedical t

Tone
Positive 82/100
Event
Deals and strategy
Published
30 Jun 2026 21:10
Source
TradingView
Stock Titan Direct company coverage

CyPath Lung sales surge as bioAffinity (NASDAQ: BIAF) expands pipeline

bioAffinity Technologies (NASDAQ: BIAF) reported a significant surge in CyPath Lung unit sales, nearly tripling in April 2026 compared to the previous year, while physician ordering sites grew by 69%. The company is expanding its pipeline with partnerships, including Philips and

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 21:10
Source
Stock Titan
Market source Direct company coverage

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

bioAffinity Technologies announced positive preclinical findings for its proprietary gene silencing technology, which selectively kills squamous and basal skin cancer cells without affecting healthy cells. This research suggests a potential topical treatment for common skin cance

Tone
Positive 81/100
Event
Market update
Published
25 Jun 2026 12:39
Source
Market source
grafa.com Direct company coverage

bioAffinity Technologies reports skin cancer siRNA preclinical results

bioAffinity Technologies announced promising preclinical results for its novel siRNA treatment, showing it selectively destroys squamous and basal skin cancer cells in vitro while leaving healthy cells unharmed. The company plans to use these findings to develop noninvasive, targ

Tone
Positive 70/100
Event
Earnings
Published
22 Jun 2026 16:33
Source
grafa.com
Moomoo Direct company coverage

BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF $3.2 MILLION OFFERING

BioAffinity Technologies announced the closing of a public offering of common stock and warrants, resulting in gross proceeds of approximately $3.2 million. The company issued over 1.7 million shares and an equivalent number of common stock purchase warrants, with net proceeds ex

Tone
Positive 60/100
Event
Market update
Published
19 Jun 2026 06:09
Source
Moomoo
Stock Titan Direct company coverage

bioAffinity Technologies (NASDAQ: BIAF) raises $3.2M in stock and pre-funded warrant sale

bioAffinity Technologies (NASDAQ: BIAF) has successfully raised approximately $3.2 million through a "best efforts" public offering of common stock and pre-funded warrants. The offering included 4,000,000 securities priced at $0.80 per share or $0.793 per pre-funded warrant, with

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 03:46
Source
Stock Titan
TradingView Direct company coverage

bioAffinity Technologies Raises $3.2M in Best-Efforts Offering, Signs Purchase and Placement Pacts

bioAffinity Technologies (BIAF) successfully completed a best-efforts public offering, raising approximately $3.2 million through the sale of common shares and pre-funded warrants. The company entered into a Securities Purchase Agreement with investors and a Placement Agency Agre

Tone
Positive 66/100
Event
Market update
Published
18 Jun 2026 20:46
Source
TradingView
Investing.com Direct company coverage

bioAffinity Technologies closes $3.2M public offering

bioAffinity Technologies (NASDAQ:BIAF) has successfully closed a public offering, raising $3.2 million in gross proceeds through the sale of 4 million common shares or pre-funded warrants at around $0.80 each. The biotechnology company, specializing in noninvasive lung cancer det

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 18:46
Source
Investing.com
Stock Titan Direct company coverage

bioAffinity sells 4M shares, raises $3.2M in public offering

bioAffinity Technologies (Nasdaq: BIAF) closed a previously announced public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 common shares or pre-funded warrants priced at $0.80 per share, with WallachBeth Capital acting as the sole placement age

Tone
Negative 35/100
Event
Market update
Published
18 Jun 2026 18:46
Source
Stock Titan
PR Newswire Direct company coverage

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

WallachBeth Capital LLC announced the closing of bioAffinity Technologies, Inc.'s public offering, raising $3.2 million in gross proceeds. The offering included 4,000,000 shares of common stock or pre-funded warrants at $0.80 per share, with WallachBeth Capital acting as the sole

Tone
Positive 59/100
Event
Market update
Published
18 Jun 2026 14:54
Source
PR Newswire
Stock Titan Direct company coverage

bioAffinity (NASDAQ: BIAF) to sell 1.04M shares, up to 2.96M pre-funded warrants

bioAffinity Technologies (NASDAQ: BIAF) has filed a prospectus to sell 1,040,000 shares of common stock at $0.80 per share and register up to 2,960,000 pre-funded warrants. The offering aims to raise estimated net proceeds of approximately $2.6 million, with a 7.5% Placement Agen

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 13:39
Source
Stock Titan
Moomoo Direct company coverage

BioAffinity Technologies Prices $3.2 Million Offering; Shares Drop 13%

BioAffinity Technologies announced the pricing of a $3.2 million underwritten public offering of 3,200,000 shares of its common stock at $1.00 per share. The offering is expected to close around June 20, 2024, and the company's shares experienced a 13% drop following the announce

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:38
Source
Moomoo
scanx.trade Direct company coverage

bioAffinity Technologies prices $3.2M public offering

bioAffinity Technologies, Inc. has priced a public offering to raise $3.2 million. The offering includes 4,000,000 shares of common stock at $0.80 per share, with pre-funded warrants available at $0.793. WallachBeth Capital, LLC is serving as the sole placement agent, and the clo

Tone
Positive 59/100
Event
Market update
Published
17 Jun 2026 14:52
Source
scanx.trade
PR Newswire Direct company coverage

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

WallachBeth Capital LLC announced the pricing of a public offering for bioAffinity Technologies, Inc., a biotechnology company focused on noninvasive lung cancer detection. The offering raised $3.2 million gross proceeds through the sale of 4,000,000 shares of common stock or pre

Tone
Positive 59/100
Event
Market update
Published
17 Jun 2026 14:40
Source
PR Newswire
Stock Titan Direct company coverage

bioAffinity sells 4M shares, aiming to raise $3.2M

bioAffinity Technologies is conducting a public offering of 4 million shares of common stock (or pre-funded warrants) at $0.80 per share, aiming to raise $3.2 million in gross proceeds. The offering, for which WallachBeth Capital is the sole placement agent, is expected to close

Tone
Negative 36/100
Event
Market update
Published
17 Jun 2026 14:40
Source
Stock Titan
TradingKey Direct company coverage

bioAffinity Technologies Inc (BIAFW) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for bioAffinity Technologies Inc (BIAFW). It indicates that the company has distributed $0.00 in dividends over the past five years and shows no record of historical stock splits. The content is presented in a data-table f

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 13:11
Source
TradingKey